Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Hepatitis C

  Free Subscription


Articles published in Clin Res Hepatol Gastroenterol

Retrieve available abstracts of 22 articles:
HTML format



Single Articles


    August 2022
  1. CAROLE S, Elena L, Benedicte LV, Abdoul-Aziz D, et al
    Acute Myeloid Leukaemia following Direct Acting Antiviral drugs in HCV-infected patients: a 10 years' retrospective single-center study.
    Clin Res Hepatol Gastroenterol. 2022 Aug 3:102000.
    PubMed     Abstract available


    May 2022
  2. DE CONTO F, Buttrini M, Dell'Anna ML, Maccari C, et al
    Detection of occult hepatitis B virus infection among subjects with isolated hepatitis B core antibodies: Results from a 3-year survey in an Italian tertiary-care hospital.
    Clin Res Hepatol Gastroenterol. 2022;46:101892.
    PubMed     Abstract available


    April 2022
  3. AZZI J, Dorival C, Cagnot C, Fontaine H, et al
    Prediction of hepatocellular carcinoma in Hepatitis C patients with advanced fibrosis after sustained virologic response.
    Clin Res Hepatol Gastroenterol. 2022 Apr 8:101923.
    PubMed     Abstract available


    January 2022
  4. KHALID SS, Abdo AA, Al-Hamoudi W, Alswat K, et al
    Association of mitotic checkpoint regulator MAD2L1 with fibrosis progression in chronic hepatitis C patients.
    Clin Res Hepatol Gastroenterol. 2022 Jan 6:101860.
    PubMed    


    December 2021
  5. COLUCCI G, Renteria SU, Lunghi G, Ceriotti F, et al
    Italian Migrants Study: an HCV and HBV Micro-Elimination Pilot Project.
    Clin Res Hepatol Gastroenterol. 2021 Dec 16:101852.
    PubMed     Abstract available


    September 2021
  6. CLEMENTE MG, Mauceri C, Grandi N, Marescalco S, et al
    No Hepatitis G virus co-infection in migrants with Hepatitis B or C hosted in Sardinia and Sicily.
    Clin Res Hepatol Gastroenterol. 2021;45:101566.
    PubMed    


  7. GEROSSIER L, Dubois A, Paturel A, Fares N, et al
    PARP inhibitors and radiation potentiate liver cell death in vitro. Do hepatocellular carcinomas have an achilles' heel?
    Clin Res Hepatol Gastroenterol. 2021;45:101553.
    PubMed     Abstract available


    July 2021
  8. TRAN A, Shili-Masmoudi S, Moga L, Chevaliez S, et al
    NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF CHRONIC INFECTION WITH HEPATITIS C VIRUS.
    Clin Res Hepatol Gastroenterol. 2021 Jul 28:101771.
    PubMed     Abstract available


    June 2021
  9. EL-BARAKY IA, Abbassi MM, Ebied FS, Hassany M, et al
    Beta-Thalassemia Major alters Sofosbuvir/Ledipasvir exposure in Hepatitis-C virus Infected Adolescent Patients.
    Clin Res Hepatol Gastroenterol. 2021 Jun 26:101747.
    PubMed     Abstract available


    May 2021
  10. SHIHA G, Soliman R, Mikhail N, Zaky S, et al
    HCC developed in CHC patients who achieved SVR following DAAs tend to display less aggressive pattern.
    Clin Res Hepatol Gastroenterol. 2021;45:101608.
    PubMed    


    April 2021
  11. NABATCHIKOVA EA, Abdurakhmanov DT, Rozina TP, Nikulkina EN, et al
    Delisting and clinical outcomes of liver transplant candidates after hepatitis C virus eradication: A long-term single-center experience.
    Clin Res Hepatol Gastroenterol. 2021 Apr 27:101714.
    PubMed     Abstract available


  12. TREPO C
    THE 2020 NOBEL PRIZE OF MEDICINE FOR THREE HEPATITIS C DISCOVERY PIONEERS : A MEDICAL HISTORY MILESTONE.
    Clin Res Hepatol Gastroenterol. 2021 Apr 10:101689.
    PubMed    


    March 2021
  13. AL-KHAYKANEE AM, Abdel-Rahman AA, Essa A, Gadallah AA, et al
    Genetic polymorphism of fibroblast growth factor receptor 2 and trinucleotide repeat-containing 9 influence the susceptibility to HCV-induced hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2021;45:101636.
    PubMed     Abstract available


  14. LAZARUS JV, Picchio CA, Guy D, Aleman S, et al
    Hepatitis C standards of care: A review of good practices since the advent of direct-acting antiviral therapy.
    Clin Res Hepatol Gastroenterol. 2021;45:101564.
    PubMed     Abstract available


    February 2021
  15. ROGER S, Ducancelle A, Le Guillou-Guillemette H, Gaudy C, et al
    HCV virology and diagnosis.
    Clin Res Hepatol Gastroenterol. 2021;45:101626.
    PubMed     Abstract available


  16. ROUDOT-THORAVAL F
    Epidemiology of hepatitis C virus infection.
    Clin Res Hepatol Gastroenterol. 2021;45:101596.
    PubMed     Abstract available


    November 2020
  17. PARLATI L, Hollande C, Pol S
    Treatment of hepatitis C virus infection.
    Clin Res Hepatol Gastroenterol. 2020 Nov 30:101578.
    PubMed     Abstract available


  18. BOLETO G, Vieira M, Saadoun D, Cacoub P, et al
    Hepatitis C virus-related vasculitis.
    Clin Res Hepatol Gastroenterol. 2020 Nov 29:101575.
    PubMed     Abstract available


    September 2020
  19. MONTASSER IF, Ibrahim AA, Farid HM, Al Balakosy AM, et al
    De novo hepatocellular carcinoma in cirrhotic hepatitis C virus: Are directly acting antivirals beneficial?
    Clin Res Hepatol Gastroenterol. 2020 Sep 5. pii: S2210-7401(20)30212.
    PubMed     Abstract available


    July 2020
  20. EL-FATTAH MA
    Predictive power of Interleukin-28B gene variants for outcome of Hepatitis C Virus genotype 4 in Egyptians: A systematic review and meta-analysis.
    Clin Res Hepatol Gastroenterol. 2020 Jul 1. pii: S2210-7401(20)30175.
    PubMed     Abstract available


    June 2020
  21. VALLET-PICHARD A, Correas JM, Dorival C, Zoulim F, et al
    Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort.
    Clin Res Hepatol Gastroenterol. 2020 Jun 25. pii: S2210-7401(20)30152.
    PubMed     Abstract available


    December 2019
  22. ZARSKI JP, David-Tchouda S, Trocme C, Margier J, et al
    Non-invasive fibrosis tests to predict complications in compensated post-hepatitis C cirrhosis.
    Clin Res Hepatol Gastroenterol. 2019 Dec 12. pii: S2210-7401(19)30256.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: